Elios Therapeutics, LLC focuses on the development of personalized therapeutic cancer vaccines, specifically targeting patients with solid tumors. Their lead product, the Tumor Lysate, Particle Only (TLPO) vaccine, is designed to stimulate the immune system by utilizing a patient's own tumor cells to create a tailored vaccine. This autologous approach allows the vaccine to present a comprehensive profile of tumor-specific antigens to the immune system, enhancing its ability to recognize and attack cancer cells. The TLPO vaccine aims to generate a robust immune response, activating T-cells that can seek out and destroy tumor cells, thereby reducing the risk of cancer recurrence.

In addition to the TLPO vaccine, Elios is also exploring the Tumor Lysate, Particle Loaded Dendritic Cell (TLPLDC) vaccine for patients with advanced solid tumors. Both vaccine types leverage a proprietary particle delivery system that enhances the presentation of tumor antigens in an inflammatory environment, mimicking the immune response to pathogens. This innovative approach not only aims to create tumor-reactive T-cells but also allows for potential combination therapies with existing treatments, such as checkpoint inhibitors. Elios' technology represents a significant advancement in cancer immunotherapy, with the potential for improved safety and long-lasting immune responses.

United States

Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product is the TLPO vaccine, an autologous therapeutic cancer vaccine designed to stimulate the immune system to recognize tumor cells and fight a patient’s specific cancer. Therapeutic cancer vaccines are an attractive immunotherapy because of their potential safety, specificity, and long-lasting response due to stimulation of immune memory.

Elios Therapeutics, LLC

Company Details